UCB
UCB
 Temps réel - 27/06 09:43:46 |
|
| 81.84EUR | +1.11% |
Métier
| Santé | ||||
 | Recherche pharmaceutique et médicale | |||
| Produits pharmaceutiques | |||
| Produits pharmaceutiques | |||
| Biopharmacies | |||
UCB est une société biopharmaceutique qui se consacre à la recherche et au développement de nouveaux médicaments et de solutions innovantes destinés aux personnes atteintes de maladies graves du système nerveux central ou immunitaire.
Nombre d'employés : 8 561 personnes.
Nombre d'employés : 8 561 personnes.
Ventes par activité
| 2020 | 2021 | ||||
| Biopharmaceuticals | 5 052.00 | 94.5% | 5 471.00 | 94.7% | |
| EUR en Millions | |||||
Ventes par région
| 2020 | 2021 | ||||
| United States | 2 759.00 | 51.6% | 2 888.00 | 50% | |
| Japan | 379.00 | 7.1% | 561.00 | 9.7% | |
| Other Countries | 403.00 | 7.5% | 429.00 | 7.4% | |
| Germany | 339.00 | 6.3% | 335.00 | 5.8% | |
| Europe- Other (excluding Belgium) | 330.00 | 6.2% | 331.00 | 5.7% | |
| Spain | 192.00 | 3.6% | 202.00 | 3.5% | |
| France (including French Territories) | 164.00 | 3.1% | 172.00 | 3% | |
| Italy | 154.00 | 2.9% | 159.00 | 2.8% | |
| United Kingdom and Ireland | 148.00 | 2.8% | 150.00 | 2.6% | |
| China | 108.00 | 2% | 140.00 | 2.4% | |
| Global | 29.00 | 0.5% | 57.00 | 1% | |
| Belgium | 47.00 | 0.9% | 47.00 | 0.8% | |
| EUR en Millions | |||||
Dirigeants
| Nom | Titre |
| Jean-Christophe Tellier | Chief Executive Officer & Executive Director |
| Sandrine Dufour | Chief Financial Officer & Executive Vice President |
| Stefan Oschmann | Chairman |
| Iris Löw-Friedrich | Chief Medical Officer, EVP & Head-Development |
| Dhavalkumar Patel | Chief Scientific Officer & Executive VP |
| Herman de Prins | Chief Information Officer |
| Kirsten Lund Jurgensen | Executive VP, Head-Supply & Technology Unit |
| Albrecht de Graeve | Independent Director |
| Ulf Arne Wiinberg | Independent Director |
| Pierre L. Gurdjian | Independent Director |
| Actionnaires |
| Nom | Actions | % |
| Financière de Tubize SA | 68 076 981 | 35,0% |
| Wellington Management Co. LLP | 12 276 178 | 6,31% |
| Fidelity Management & Research Co. LLC | 7 710 794 | 3,96% |
| UCB SA | 5 480 222 | 2,82% |
| The Vanguard Group, Inc. | 3 292 676 | 1,69% |
| Norges Bank Investment Management | 2 887 682 | 1,48% |
| Schroder Investment Management Ltd. | 2 648 096 | 1,36% |
| Baillie Gifford & Co. | 2 237 419 | 1,15% |
| Artisan Partners LP | 2 034 598 | 1,05% |
| Degroof Petercam Asset Management SA | 1 471 141 | 0,76% |
Coordonnées société
Allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
Places et indices
| - Compartiment A |
| - BEL 20 / Euronext 100, PEA, STOXX Europe 600 |
Codes boursiers
| - Code Bloomberg : | UCB:BB |
| - Code Reuters : | UCB.BR |
Secteur Biopharmacies
| Var. 1janv | Capi. (M$) | ||
 | |||
| UCB SA | -24.53% | 16 152 | |
| |||
| CSL LIMITED | -6.70% | 90 814 | |
| SAMSUNG BIOLOGICS CO.,LTD. | -7.97% | 45 825 | |
| WUXI BIOLOGICS (CAYMAN) INC. | -16.59% | 41 498 | |
| BIOGEN INC. | -11.67% | 31 038 | |
| CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | -19.19% | 24 084 | |
| UCB | -19.34% | 16 152 | |
| BIOMARIN PHARMACEUTICAL INC. | -1.70% | 16 067 | |
| WALVAX BIOTECHNOLOGY CO., LTD. | -14.79% | 11 466 | |
| GRIFOLS, S.A. | 9.81% | 11 300 | |
| BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | -12.27% | 9 798 | |
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | -22.50% | 9 381 | |
| CELLTRION HEALTHCARE CO., LTD. | -15.34% | 8 160 | |
| SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | -31.25% | 7 092 | |
| INNOVENT BIOLOGICS, INC. | -25.08% | 6 755 | |
| SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 17.40% | 6 334 | |
| SK BIOSCIENCE CO.,LTD. | -54.44% | 6 098 | |
| HUALAN BIOLOGICAL ENGINEERING INC. | -25.15% | 5 948 | |
| BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | -16.54% | 4 962 | |
| APELLIS PHARMACEUTICALS, INC. | -2.16% | 4 928 | |
| CANSINO BIOLOGICS INC. | 0.00% | 4 815 | |
Portefeuille de Marques
